Quantcast
Last updated on April 21, 2014 at 8:55 EDT

Latest HUMIRA Stories

2011-11-07 05:00:00

ABBOTT PARK, Ill., Nov. 7, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-1 study of HUMIRA® (adalimumab) in patients with active non-radiographic axial spondyloarthritis (axSpA). AxSpA is a debilitating condition that primarily presents with inflammatory low back pain and can be accompanied by the presence of the HLA-B27 gene, arthritis, and inflammation in the eye and/or gastrointestinal tract. At week 12, more than twice as...

2011-11-06 05:00:00

ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively. In both studies, patients were assessed for disease activity,...

2011-11-02 05:00:00

ABBOTT PARK, Ill., Nov. 2, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago. The presentations include data on rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and spondyloarthritis (SpA), as well as health...

2011-09-28 08:20:01

Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch Humira(R) (adalimumab) Prefilled Syringe 20mg/0.4mL, a fully human anti-TNF-α monoclonal antibody for the treatment of polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight, on September 29.Humira Prefilled Syringe 20mg/0.4mL received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare on July 1 of this...

2011-09-26 04:20:01

Tokyo, Sept 26, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have submitted an application in Japan seeking approval of inhibition of structural damage of joints in rheumatoid arthritis as an additional indication for Humira(R) (adalimumab; recombinant) Pre-filled Syringe 40 mg/0.8 mL, a fully human anti-TNF-alpha monoclonal antibody jointly developed by the two companies.The submission is based on the results of a double-blind study (HOPEFUL1...

2011-07-29 11:20:00

DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia. "Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis. After taking the drug for approximately ten months, Bo's parents noticed unusual bruising covering his body while on a family vacation," says drug defect attorney Andy Vickery. "Bo...

2011-07-01 08:35:02

Tokyo, July 1, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for polyarticular juvenile idiopathic arthritis (JIA) as an additional indication of Humira(R) (adalimumab) Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF-α monoclonal antibody jointly developed by the two companies in Japan.In addition to the new indication,...

2011-06-28 06:01:00

LONDON, June 28, 2011 /PRNewswire/ -- Rheumatoid arthritis treatment Humira will assume Lipitor's crown as the world's biggest selling drug, while Pfizer will cling on to its ranking as the biggest seller of prescription medicines through to 2016, according to the World Preview 2016 (second edition) report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. Lipitor's patent expiry this year precipitates the steepest decline in the...

2011-06-13 07:00:00

MEMPHIS, June 13, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man. Army veteran Fred Delano was prescribed Humira in October of 2008 for psoriatic arthritis. After taking the drug for two and-a-half months, Delano was hospitalized and diagnosed with disseminated histoplasmosis, an extremely dangerous side...

2011-05-10 08:00:00

ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago. Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated...